<?xml version="1.0" encoding="iso-8859-1" ?><rss version="0.91">
<channel>
<title></title>
<link>http://www.searchforvideo.com</link>
<description>SearchForVideo.com  videos</description>
<language>en-us</language>
<copyright>Copyright 2005 SearchForVideo.com</copyright>
<managingEditor>info@searchforvideo.com</managingEditor>
<webMaster>info@searchforvideo.com</webMaster>

<item>    
<title><![CDATA[ High Dose Cyclophosphamide: a cure for autoimmune disease? ]]></title>
<link><![CDATA[ http://www.searchforvideo.com//watchclip.php?title=High+Dose+Cyclophosphamide%3A+a+cure+for+autoimmune+disease%3F&link=http%3A%2F%2Fapi.searchvideo.com%2Frd%3Fi%3D2100082272%26a%3D274eb77a8bbe365bee32b5722c1be346%26p%3D2%26q%3Dcyclophosphamide%26vl%3D1090760510%25202112457174%25204098218182%25203805656750%2520131390196%2520501002244%2520630106050%25203173939946%2520536272274%2520708940416%2520&description=High+Dose+Cyclophosphamide%3A+a+cure+for+autoimmune+disease%3F&source=AOL+Video&image=http%3A%2F%2Fthumbnails.truveo.com%2F0000%2F65%2F53%2F65533C7213A65577E1A07A.jpg&category=search ]]></link>
<description><![CDATA[ Source: AOL Video High Dose Cyclophosphamide: a cure for autoimmune disease? ]]> </description>    
</item>
<item>    
<title><![CDATA[ Acute Therapies: Steroids, IVIG, Plasmaexchange and ... ]]></title>
<link><![CDATA[ http://www.searchforvideo.com//watchclip.php?title=Acute+Therapies%3A+Steroids%2C+IVIG%2C+Plasmaexchange+and+...&link=http%3A%2F%2Fapi.searchvideo.com%2Frd%3Fi%3D1093176804%26a%3D274eb77a8bbe365bee32b5722c1be346%26p%3D1%26q%3Dcyclophosphamide%26vl%3D1090760510%25202112457174%25204098218182%25203805656750%2520131390196%2520501002244%2520630106050%25203173939946%2520536272274%2520708940416%2520&description=2008+Rare+Neuroimmunologic+Disorders+Symposium%2C+Acute+Therapies%3A+Steroids%2C+IVIG%2C+Plasmaexchange+and+Cyclophosphamide%2C+Benjamin+M.+Greenberg+...&source=AOL+Video&image=http%3A%2F%2Fthumbnails.truveo.com%2F0005%2FDD%2F64%2FDD64F28537C74D82E40FF9.jpg&category=search ]]></link>
<description><![CDATA[ Source: AOL Video 2008 Rare Neuroimmunologic Disorders Symposium, Acute Therapies: Steroids, IVIG, Plasmaexchange and Cyclophosphamide, Benjamin M. Greenberg ... ]]> </description>    
</item>
<item>    
<title><![CDATA[ Zoledronic Acid  Zometa  in Neuroblastoma ]]></title>
<link><![CDATA[ http://www.searchforvideo.com//watchclip.php?title=Zoledronic+Acid++Zometa++in+Neuroblastoma&link=http%3A%2F%2Fapi.searchvideo.com%2Frd%3Fi%3D3618677128%26a%3D274eb77a8bbe365bee32b5722c1be346%26p%3D2%26q%3Dcyclophosphamide%26vl%3D2112457174%25203615724269%25204098218182%25203805656750%2520501002244%2520630106050%2520131390196%25203173939946%2520536272274%2520708940416%2520&description=Heidi+V.+Russell%2C+M.D.+Assistant+Professor%2C+Department+of+Pediatrics%2C+Section+of+Hematology+Oncology%2C+Baylor+College+of+Medicine+and+study+chair+of+the+NANT+trial+A+Phase+I+Study+of+Zoledronic+Acid++Zometa++with+Cyclophosphamide+in+Children+with+Recurrent%2FRefractory+Neuroblastoma+and+Cortical+Bone+Involvement.+In+this+presentation+she+discusses+bone+metastases+and+Zoledronic+Acid.+This+presentation+was+made+at+the+Children%27s+Neuroblastoma+Cancer+Foundation%27s+Neuroblas...&source=AOL+Video&image=http%3A%2F%2Fthumbnail.search.aolcdn.com%2Fvsthumb5%2Ftn%2F81%2FE0%2F81E0E1BF52BF7E29CECF3A.jpg&category=search ]]></link>
<description><![CDATA[ Source: AOL Video Heidi V. Russell, M.D. Assistant Professor, Department of Pediatrics, Section of Hematology Oncology, Baylor College of Medicine and study chair of the NANT trial A Phase I Study of Zoledronic Acid  Zometa  with Cyclophosphamide in Children with Recurrent/Refractory Neuroblastoma and Cortical Bone Involvement. In this presentation she discusses bone metastases and Zoledronic Acid. This presentation was made at the Children's Neuroblastoma Cancer Foundation's Neuroblas... ]]> </description>    
</item>
<item>    
<title><![CDATA[ : FDA APPROVES TWO NEW INDICATIONS FOR RITUXAN  RITUXIMAB ]]></title>
<link><![CDATA[ http://www.searchforvideo.com//watchclip.php?title=%3A+FDA+APPROVES+TWO+NEW+INDICATIONS+FOR+RITUXAN++RITUXIMAB&link=http%3A%2F%2Fapi.searchvideo.com%2Frd%3Fi%3D634912751%26a%3D274eb77a8bbe365bee32b5722c1be346%26p%3D6%26q%3Dcyclophosphamide%26vl%3D2112457174%25203615724269%25204098218182%25203805656750%2520501002244%2520630106050%2520131390196%25203173939946%2520536272274%2520708940416%2520&description=FDA+APPROVES+TWO+NEW+INDICATIONS+FOR+RITUXAN++RITUXIMAB++IN+PATIENTS+WITH+NON+HODGKIN%27S+LYMPHOMAThe+U.S.+Food+and+Drug+Administration++FDA++has+approved+two+additional+uses+for+Rituxan+for+patients+with+CD20+positive%2C+B+cell+non+Hodgkin%27s+lymphoma++NHL+.+One+new+indication+for+Rituxan+is+for+first+line+treatment+of+previously+untreated+patients+with+follicular+NHL+in+combination+with+CVP++cyclophosphamide%2C+vincristine+and+prednisolone++chemotherapy.+%26c...&source=AOL+Video&image=http%3A%2F%2Fthumbnails.truveo.com%2F0004%2FEC%2F04%2FEC04EA2211168015B5C47A.jpg&category=search ]]></link>
<description><![CDATA[ Source: AOL Video FDA APPROVES TWO NEW INDICATIONS FOR RITUXAN  RITUXIMAB  IN PATIENTS WITH NON HODGKIN'S LYMPHOMAThe U.S. Food and Drug Administration  FDA  has approved two additional uses for Rituxan for patients with CD20 positive, B cell non Hodgkin's lymphoma  NHL . One new indication for Rituxan is for first line treatment of previously untreated patients with follicular NHL in combination with CVP  cyclophosphamide, vincristine and prednisolone  chemotherapy. &c... ]]> </description>    
</item>
<item>    
<title><![CDATA[ 25461 FDA APPROVES TWO NEW INDICATIONS FOR RITUXAN  RITUXIMAB  IN PATIENTS... ]]></title>
<link><![CDATA[ http://www.searchforvideo.com//watchclip.php?title=25461+FDA+APPROVES+TWO+NEW+INDICATIONS+FOR+RITUXAN++RITUXIMAB++IN+PATIENTS...&link=http%3A%2F%2Fapi.searchvideo.com%2Frd%3Fi%3D126512608%26a%3D274eb77a8bbe365bee32b5722c1be346%26p%3D7%26q%3Dcyclophosphamide%26vl%3D2112457174%25203615724269%25204098218182%2520501002244%25203805656750%2520630106050%2520131390196%25203173939946%2520536272274%2520175165204%2520&description=FDA+APPROVES+TWO+NEW+INDICATIONS+FOR+RITUXAN++RITUXIMAB++IN+PATIENTS+WITH+NON+HODGKINS+LYMPHOMA+The+U.S.+Food+and+Drug+Administration++FDA++has+approved+two+additional+uses+for+Rituxan+for+patients+with+CD20+positive%2C+B+cell+non+Hodgkin%27s+lymphoma++NHL+.+One+new+indication+for+Rituxan+is+for+first+line+treatment+of+previously+untreated+patients+with+follicular+NHL+in+combination+with+CVP++cyclophosphamide%2C+vincristine+and+prednisolone++chemotherapy.+The+second+new+indic...&source=AOL+Video&image=http%3A%2F%2Fthumbnails.truveo.com%2F0004%2F83%2F47%2F83471C4029A72F22AC34E8.jpg&category=search ]]></link>
<description><![CDATA[ Source: AOL Video FDA APPROVES TWO NEW INDICATIONS FOR RITUXAN  RITUXIMAB  IN PATIENTS WITH NON HODGKINS LYMPHOMA The U.S. Food and Drug Administration  FDA  has approved two additional uses for Rituxan for patients with CD20 positive, B cell non Hodgkin's lymphoma  NHL . One new indication for Rituxan is for first line treatment of previously untreated patients with follicular NHL in combination with CVP  cyclophosphamide, vincristine and prednisolone  chemotherapy. The second new indic... ]]> </description>    
</item>
<item>    
<title><![CDATA[ Acute Therapies ]]></title>
<link><![CDATA[ http://www.searchforvideo.com//watchclip.php?title=Acute+Therapies&link=http%3A%2F%2Fapi.searchvideo.com%2Frd%3Fi%3D4108881018%26a%3D274eb77a8bbe365bee32b5722c1be346%26p%3D3%26q%3Dcyclophosphamide%26vl%3D2112457174%25203615724269%25204098218182%2520501002244%25203805656750%2520630106050%2520131390196%25203173939946%2520536272274%2520175165204%2520&description=2004+Rare+Neuroimmunologic+Disorders+Symposium+Acute+Therapies+B.+Weinshenker%2C+MD+Corticosteroids%2C+Plasma+Exchange%2C+Cyclophosphamide&source=AOL+Video&image=http%3A%2F%2Fthumbnail.search.aolcdn.com%2Ftruveo%2Fimages%2Fthumbnails%2F65%2F28%2F6528BD125CE44E.jpg&category=search ]]></link>
<description><![CDATA[ Source: AOL Video 2004 Rare Neuroimmunologic Disorders Symposium Acute Therapies B. Weinshenker, MD Corticosteroids, Plasma Exchange, Cyclophosphamide ]]> </description>    
</item>
<item>    
<title><![CDATA[ 23533 FDA APPROVES HERCEPTIN FOR THE ADJUVANT TREATMENT OF ]]></title>
<link><![CDATA[ http://www.searchforvideo.com//watchclip.php?title=23533+FDA+APPROVES+HERCEPTIN+FOR+THE+ADJUVANT+TREATMENT+OF&link=http%3A%2F%2Fapi.searchvideo.com%2Frd%3Fi%3D534690007%26a%3D274eb77a8bbe365bee32b5722c1be346%26p%3D9%26q%3Dcyclophosphamide%26vl%3D2112457174%25203615724269%25204098218182%2520501002244%25203805656750%2520630106050%2520131390196%25203173939946%2520536272274%2520175165204%2520&description=FDA+APPROVES+HERCEPTIN+FOR+THE+ADJUVANT+TREATMENT+OF+HER2+POSITIVE+NODE+POSITIVE+BREAST+CANCERGenentech%2C+Inc.+announced+today+that+the+U.S.+Food+and+Drug+Administration++FDA++approved+Herceptin++Trastuzumab++for+the+adjuvant+treatment+of+HER2+positive+node+positive+breast+cancer%2C+as+part+of+a+treatment+regimen+containing+doxorubicin%2C+cyclophosphamide%2C+and+paclitaxel.+The+FDA+approval+was+based+on+data+from+an+interim+joint+analysis+of+more+than+3%2C500+patients+enrolled+in+...&source=AOL+Video&image=http%3A%2F%2Fthumbnails.truveo.com%2F0002%2F47%2F49%2F47496B2051C6A67267B5EE.jpg&category=search ]]></link>
<description><![CDATA[ Source: AOL Video FDA APPROVES HERCEPTIN FOR THE ADJUVANT TREATMENT OF HER2 POSITIVE NODE POSITIVE BREAST CANCERGenentech, Inc. announced today that the U.S. Food and Drug Administration  FDA  approved Herceptin  Trastuzumab  for the adjuvant treatment of HER2 positive node positive breast cancer, as part of a treatment regimen containing doxorubicin, cyclophosphamide, and paclitaxel. The FDA approval was based on data from an interim joint analysis of more than 3,500 patients enrolled in ... ]]> </description>    
</item>
<item>    
<title><![CDATA[ FDA APPROVES TWO NEW INDICATIONS FOR RITUXAN... ]]></title>
<link><![CDATA[ http://www.searchforvideo.com//watchclip.php?title=FDA+APPROVES+TWO+NEW+INDICATIONS+FOR+RITUXAN...&link=http%3A%2F%2Fapi.searchvideo.com%2Frd%3Fi%3D3804582291%26a%3D274eb77a8bbe365bee32b5722c1be346%26p%3D5%26q%3Dcyclophosphamide%26vl%3D2112457174%25203615724269%25204098218182%2520501002244%25203805656750%2520630106050%2520131390196%25203173939946%2520536272274%2520175165204%2520&description=FDA+APPROVES+TWO+NEW+INDICATIONS+FOR+RITUXAN++RITUXIMAB++IN+PATIENTS+WITH+NON+HODGKINS+LYMPHOMA+The+U.S.+Food+and+Drug+Administration++FDA++has+approved+two+additional+uses+for+Rituxan+for+patients+with+CD20+positive%2C+B+cell+non+Hodgkin%27s+lymphoma++NHL+.+One+new+indication+for+Rituxan+is+for+first+line+treatment+of...&source=AOL+Video&image=http%3A%2F%2Fthumbnail.search.aolcdn.com%2Ftruveo%2Fimages%2Fthumbnails%2F8B%2F8E%2F8B8EB7F8B0E2E0.jpg&category=search ]]></link>
<description><![CDATA[ Source: AOL Video FDA APPROVES TWO NEW INDICATIONS FOR RITUXAN  RITUXIMAB  IN PATIENTS WITH NON HODGKINS LYMPHOMA The U.S. Food and Drug Administration  FDA  has approved two additional uses for Rituxan for patients with CD20 positive, B cell non Hodgkin's lymphoma  NHL . One new indication for Rituxan is for first line treatment of... ]]> </description>    
</item>
<item>    
<title><![CDATA[ FDA APPROVES HERCEPTIN FOR THE ADJUVANT TREATMENT OF HER2 POSI ]]></title>
<link><![CDATA[ http://www.searchforvideo.com//watchclip.php?title=FDA+APPROVES+HERCEPTIN+FOR+THE+ADJUVANT+TREATMENT+OF+HER2+POSI&link=http%3A%2F%2Fwww.metacafe.com%2Fwatch%2F334528%2Ffda_approves_herceptin_for_the_adjuvant_treatment_of_her2_posi%2F&description=HERCEPTIN+REDUCED+THE+RISK+OF+BREAST+CANCER+RECURRENCE+BY+52+PERCENT+IN+PIVOTAL+STUDIES+++++++ONLY+TARGETED+BIOLOGIC+THERAPY+APPROVED+FOR+USE+IN+ADJUVANT+AND+METASTATIC+HER2+POSITIVE+BREAST+CANCER++++Genentech%2C+Inc.+announced+today+that+the+U.S.+Food+and+Drug+Administration++FDA++approved+Herceptin++Trastuzumab++for+the+adjuvant+treatment+of+HER2+positive+node+positive+breast+cancer%2C+as+part+of+a+treatment+regimen+containing+doxorubicin%2C+cyclophosphamide%2C+and+paclitaxel.+The+FDA+approval+w&source=Metacafe&image=http%3A%2F%2Fs.mcstatic.com%2Fthumb%2F334528%2F2452562%2F4%2Fdirectors_cut%2F0%2F1%2Ffda_approves_herceptin_for_the_adjuvant_treatment_of_her2_posi.jpg&category=search ]]></link>
<description><![CDATA[ Source: Metacafe HERCEPTIN REDUCED THE RISK OF BREAST CANCER RECURRENCE BY 52 PERCENT IN PIVOTAL STUDIES       ONLY TARGETED BIOLOGIC THERAPY APPROVED FOR USE IN ADJUVANT AND METASTATIC HER2 POSITIVE BREAST CANCER    Genentech, Inc. announced today that the U.S. Food and Drug Administration  FDA  approved Herceptin  Trastuzumab  for the adjuvant treatment of HER2 positive node positive breast cancer, as part of a treatment regimen containing doxorubicin, cyclophosphamide, and paclitaxel. The FDA approval w ]]> </description>    
</item>
</channel>
</rss>
